Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.

Cancer letters - 28 Aug 2006

Campbell Ian G, Eccles Diana M, Choong David Y H

Abstract excerpt

A functional T to G germline polymorphism in the promoter region of MDM2 (SNP309) has been reported to profoundly accelerate tumor formation suggesting that it may also represent a powerful cancer predisposing allele. To investigate the role of SNP309 in cancer predisposition we undertook a case-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged, 80 and over
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Case-Control Studies

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins c-mdm2

Share to Risk Factors

Source

Identifiers

PMID: 16239061
DOI: 10.1016/j.canlet.2005.09.003

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-16239061-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.PMID 16239061Read ↗

MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk.Semantic proximity Read ↗

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.Semantic proximity Read ↗

MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.Semantic proximity Read ↗

Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.Semantic proximity Read ↗

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.Semantic proximity Read ↗

MDM2 SNP309 and cancer risk: a combined analysis.Semantic proximity Read ↗

No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites.Semantic proximity Read ↗

Association of breast cancer outcome with status of p53 and MDM2 SNP309.Semantic proximity Read ↗

MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.Semantic proximity Read ↗

Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk.Semantic proximity Read ↗

MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.Semantic proximity Read ↗

MDM2 SNP309 G allele decreases risk but does not affect onset age or survival of Chinese leukaemia patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.